Investors

(HM Government sixth annual report on the Bioscience and Health Technology Database)

The technological and scientific advancements in a start-up drug company make them fruitful opportunities for portfolio investors.

Investment in iQur

iQur, with vaccines in development for phase I testing, poses an exciting opportunity for investors, with a clear strategy for further development, early rounds of successful research, and relatively modest investment options.

iQur is a private company, only opening new rounds of investment periodically. Current stakeholders come from diverse backgrounds, including venture capital, managed investment funds and individual business angels.

In addition to private investment, iQur has been successful in obtaining international grants. iQur led a consortium that won £3.8 million funding from the EU Framework 7 Program to develop a universal influenza vaccine. In 2013 we successfully applied to the TSB-MRC Biocatalyst Fund to apply the Tandem Core platform to malaria in collaboration with Professor Adrian Hill at the Jenner Institute, University of Oxford. Funding from the TSB also supports a joint program with DTRA developing vaccines for Burkholderia.

An investment in the Company is intended for EIS relief. Investments of this nature carry risks to your capital as well as potential rewards.

For more on investment opportunities at iQur contact William Rosenberg.

Governance

The company is governed by a Board who have adopted corporate governance guidelines, to ensure best practice in iQur’s growth, to promote the interests of stockholders, and to establish a set of common principles by which the company will be managed by investors and directors.